The use of tafasitamab in diffuse large B-cell lymphoma. (July 2021)

• Record Type: Journal Article
• Authors: Düll, Johannes; Topp, Max; Salles, Gilles
• Is Part Of: Therapeutic advances in hematology. Volume 12(2021)
• Publication Date: 2021-07
• Subjects: anti-CD19 -- clinical data -- diffuse large B-cell lymphoma -- DLBCL -- lenalidomide -- mode of action -- monoclonal antibody -- real-world evidence -- tafasitamab; Hematology -- Periodicals; Hematologic Diseases -- therapy -- Periodicals; Hematology -- Periodicals; 616.15005
• DOI: 10.1177/20406207211027458
• Languages: English
• ISSNs: 2040-6207

Abstract

Patients who relapse or are refractory after first-line therapy for diffuse large B-cell lymphoma (DLBCL) frequently have poor prognoses, especially when they are not candidates for autologous stem cell transplant (ASCT). Tafasitamab is a humanized monoclonal anti-CD19 antibody that has recently been approved by the FDA in combination with lenalidomide for the treatment of relapsed/refractory (R/R) DLBCL in patients who are not eligible for ASCT. Tafasitamab has an Fc region which has been modified to have an increased affinity for Fcγ receptors, to potentiate antibody-dependent cellular cytotoxicity and antibody-dependent cell-mediated phagocytosis. Here, we review the development, mode of action and clinical data for tafasitamab in combination with lenalidomide in R/R DLBCL, and discuss the various ways in which this novel antibody could be utilized in the treatment sequence to improve clinical outcomes for patients with DLBCL.